Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

NCT04223648 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding

Conditions

Malignant Melanoma

Interventions

DRUG: tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy

Sponsor

Yale University

Collaborators

[object Object]